1887

Chapter 19 : Lipid Mediators in Inflammation

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in
Zoomout

Lipid Mediators in Inflammation, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819194/9781555819187_Chap19-1.gif /docserver/preview/fulltext/10.1128/9781555819194/9781555819187_Chap19-2.gif

Abstract:

Before we discuss lipids and their role in homeostasis and host defense, we will recount the essence of the inflammatory response. Inflammation is a reaction of the microcirculation; it’s a protective response initiated after infection or injury. While both local and systemic responses can be activated, inflammation is an essential biological process with the objective of eliminating the inciting stimulus, promoting tissue repair/wound healing, and, in the case of infection, establishing memory such that the host mounts a faster and more specific response upon a future encounter. The acute inflammatory response is a complex yet highly coordinated sequence of events involving a large number of molecular, cellular, and physiological changes. It begins with the production of soluble mediators (complement, chemokines, cytokines, eicosanoids—including prostaglandins [PGs], free radicals, vasoactive amines, etc.) by resident cells in the injured/infected tissue (i.e., tissue macrophages, dendritic cells, lymphocytes, endothelial cells, fibroblasts, and mast cells), concomitant with the upregulation of cell adhesion molecules on both leukocytes and endothelial cells that promote the exudation of proteins and influx of granulocytes from blood ( ). Upon arrival, these leukocytes, typically polymorphonuclear leukocytes (PMNs) in the case of nonspecific inflammation or eosinophils in response to allergens, function primarily to phagocytose and eliminate foreign microorganisms via distinct intracellular (superoxide, myeloperoxidase, proteases, and lactoferrins) and/or extracellular (neutrophil extracellular traps) killing mechanisms ( ). It is likely that the magnitude of the infectious load and its eventual neutralization signal the next phase of active anti-inflammation and proresolution ( ).

Citation: Bennett M, Gilroy D. 2017. Lipid Mediators in Inflammation, p 343-366. In Gordon S (ed), Myeloid Cells in Health and Disease. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.MCHD-0035-2016
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555819194.chap19
1. Serhan C,, Ward P,, Gilroy D . 2010. Fundamentals of Inflammation. Cambridge University Press, Cambridge, United Kingdom.
2. Segal AW . 2005. How neutrophils kill microbes. Annu Rev Immunol 23 : 197 223.
3. Serhan CN,, Savill J . 2005. Resolution of inflammation: the beginning programs the end. Nat Immunol 6 : 1191 1197.
4. Majno G,, Joris I . 2004. Cells, Tissues and Disease: Principles of General Pathology, 2nd ed. Oxford University Press, New York, NY.
5. Buckley CD,, Gilroy DW,, Serhan CN . 2014. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity 40 : 315 327.
6. Buckley CD,, Gilroy DW,, Serhan CN,, Stockinger B,, Tak PP . 2013. The resolution of inflammation. Nat Rev Immunol 13 : 59 66.
7. Segal AW,, Geisow M,, Garcia R,, Harper A,, Miller R . 1981. The respiratory burst of phagocytic cells is associated with a rise in vacuolar pH. Nature 290 : 406 409.
8. Gilroy DW,, Colville-Nash PR,, McMaster S,, Sawatzky DA,, Willoughby DA,, Lawrence T . 2003. Inducible cyclooxygenase-derived 15deoxyΔ 12–14PGJ 2 brings about acute inflammatory resolution in rat pleurisy by inducing neutrophil and macrophage apoptosis. FASEB J 17 : 2269 2271.
9. Nibbs RJ,, Graham GJ . 2013. Immune regulation by atypical chemokine receptors. Nat Rev Immunol 13 : 815 829.
10. Ariel A,, Fredman G,, Sun YP,, Kantarci A,, Van Dyke TE,, Luster AD,, Serhan CN . 2006. Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat Immunol 7 : 1209 1216.
11. Piper P,, Vane J . 1971. The release of prostaglandins from lung and other tissues. Ann N Y Acad Sci 180 : 363 385.
12. Samuelsson B,, Dahlén SE,, Lindgren JA,, Rouzer CA,, Serhan CN . 1987. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237 : 1171 1176.
13. Serhan CN,, Hamberg M,, Samuelsson B . 1984. Trihydroxytetraenes: a novel series of compounds formed from arachidonic acid in human leukocytes. Biochem Biophys Res Commun 118 : 943 949.
14. Capdevila JH,, Falck JR,, Dishman E,, Karara A . 1990. Cytochrome P-450 arachidonate oxygenase. Methods Enzymol 187 : 385 394.
15. Pagels WR,, Sachs RJ,, Marnett LJ,, Dewitt DL,, Day JS,, Smith WL . 1983. Immunochemical evidence for the involvement of prostaglandin H synthase in hydroperoxide-dependent oxidations by ram seminal vesicle microsomes. J Biol Chem 258 : 6517 6523.
16. Hamberg M,, Samuelsson B . 1973. Detection and isolation of an endoperoxide intermediate in prostaglandin biosynthesis. Proc Natl Acad Sci U S A 70 : 899 903.
17. Nugteren DH,, Hazelhof E . 1973. Isolation and properties of intermediates in prostaglandin biosynthesis. Biochim Biophys Acta 326 : 448 461.
18. Dubois RN,, Abramson SB,, Crofford L,, Gupta RA,, Simon LS,, Van De Putte LB,, Lipsky PE . 1998. Cyclooxygenase in biology and disease. FASEB J 12 : 1063 1073.
19. Shimizu T,, Yamamoto S,, Hayaishi O . 1982. Purification of PGH-PGD isomerase from rat brain. Methods Enzymol 86 : 73 77.
20. Tanaka Y,, Ward SL,, Smith WL . 1987. Immunochemical and kinetic evidence for two different prostaglandin H-prostaglandin E isomerases in sheep vesicular gland microsomes. J Biol Chem 262 : 1374 1381.
21. Hayashi H,, Fujii Y,, Watanabe K,, Urade Y,, Hayaishi O . 1989. Enzymatic conversion of prostaglandin H 2 to prostaglandin F by aldehyde reductase from human liver: comparison to the prostaglandin F synthetase from bovine lung. J Biol Chem 264 : 1036 1040.
22. DeWitt DL,, Smith WL . 1983. Purification of prostacyclin synthase from bovine aorta by immunoaffinity chromatography. Evidence that the enzyme is a hemoprotein. J Biol Chem 258 : 3285 3293.
23. Ullrich V,, Haurand M . 1983. Thromboxane synthase as a cytochrome P450 enzyme. Adv Prostaglandin Thromboxane Leukot Res 11 : 105 110.
24. Bezugla Y,, Kolada A,, Kamionka S,, Bernard B,, Scheibe R,, Dieter P . 2006. COX-1 and COX-2 contribute differentially to the LPS-induced release of PGE 2 and TxA 2 in liver macrophages. Prostaglandins Other Lipid Mediat 79 : 93 100.
25. Naraba H,, Murakami M,, Matsumoto H,, Shimbara S,, Ueno A,, Kudo I,, Oh-ishi S . 1998. Segregated coupling of phospholipases A 2, cyclooxygenases, and terminal prostanoid synthases in different phases of prostanoid biosynthesis in rat peritoneal macrophages. J Immunol 160 : 2974 2982.
26. Jakobsson PJ,, Thorén S,, Morgenstern R,, Samuelsson B . 1999. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci U S A 96 : 7220 7225.
27. Penglis PS,, Cleland LG,, Demasi M,, Caughey GE,, James MJ . 2000. Differential regulation of prostaglandin E 2 and thromboxane A 2 production in human monocytes: implications for the use of cyclooxygenase inhibitors. J Immunol 165 : 1605 1611.
28. Brock TG,, McNish RW,, Peters-Golden M . 1999. Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E 2 . J Biol Chem 274 : 11660 11666.
29. Hirai H,, Tanaka K,, Yoshie O,, Ogawa K,, Kenmotsu K,, Takamori Y,, Ichimasa M,, Sugamura K,, Nakamura M,, Takano S,, Nagata K . 2001. Prostaglandin D 2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 193 : 255 261.
30. Monneret G,, Gravel S,, Diamond M,, Rokach J,, Powell WS . 2001. Prostaglandin D 2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 98 : 1942 1948.
31. Xue L,, Gyles SL,, Wettey FR,, Gazi L,, Townsend E,, Hunter MG,, Pettipher R . 2005. Prostaglandin D 2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells. J Immunol 175 : 6531 6536.
32. von Euler US . 1936. On the specific vaso-dilating and plain muscle stimulating substances from accessory genital glands in man and certain animals (prostaglandin and vesiglandin). J Physiol 88 : 213 234.
33. Eckenfels A,, Vane JR . 1972. Prostaglandins, oxygen tension and smooth muscle tone. Br J Pharmacol 45 : 451 462.
34. Ferreira SH,, Herman A,, Vane JR . 1972. Proceedings: prostaglandin generation maintains the smooth muscle tone of the rabbit isolated jejunum. Br J Pharmacol 44 : 328P 329P.
35. Main IH . 1964. The inhibitory actions of prostaglandins on respiratory smooth muscle. Br Pharmacol Chemother 22 : 511 519.
36. Williams TJ . 1979. Prostaglandin E 2, prostaglandin I 2 and the vascular changes of inflammation. Br J Pharmacol 65 : 517 524.
37. Williams TJ,, Jose PJ . 1981. Mediation of increased vascular permeability after complement activation. Histamine-independent action of rabbit C5a. J Exp Med 153 : 136 153.
38. Ferreira SH,, Nakamura M,, de Abreu Castro MS . 1978. The hyperalgesic effects of prostacyclin and prostaglandin E 2 . Prostaglandins 16 : 31 37.
39. Feldberg W,, Gupta KP . 1973. Pyrogen fever and prostaglandin-like activity in cerebrospinal fluid. J Physiol 228 : 41 53.
40. Feldberg W,, Saxena PN . 1971. Fever produced by prostaglandin E 1 . J Physiol 217 : 547 556.
41. Milton AS,, Wendlandt S . 1971. Effects on body temperature of prostaglandins of the A, E and F series on injection into the third ventricle of unanaesthetized cats and rabbits. J Physiol 218 : 325 336.
42. Moncada S,, Gryglewski R,, Bunting S,, Vane JR . 1976. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263 : 663 665.
43. Kaley G,, Hintze TH,, Panzenbeck M,, Messina EJ . 1985. Role of prostaglandins in microcirculatory function. Adv Prostaglandin Thromboxane Leukot Res 13 : 27 35.
44. Hata AN,, Breyer RM . 2004. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 103 : 147 166.
45. Higgs EA,, Moncada S,, Vane JR . 1978. Inflammatory effects of prostacyclin (PGI 2) and 6-oxo-PGF in the rat paw. Prostaglandins 16 : 153 162.
46. Komoriya K,, Ohmori H,, Azuma A,, Kurozumi S,, Hashimoto Y,, Nicolaou KC,, Barnette WE,, Magolda RL . 1978. Prostaglandin I 2 as a potentiator of acute inflammation in rats. Prostaglandins 15 : 557 564.
47. Lewis AJ,, Nelson DJ,, Sugrue MF . 1975. On the ability of prostaglandin E 1, and arachidonic acid to modulate experimentally induced oedema in the rat paw. Br J Pharmacol 55 : 51 56.
48. Moncada S,, Ferreira SH,, Vane JR . 1973. Prostaglandins, aspirin-like drugs and the oedema of inflammation. Nature 246 : 217 219.
49. Williams TJ,, Morley J . 1973. Prostaglandins as potentiators of increased vascular permeability in inflammation. Nature 246 : 215 217.
50. Yuhki K,, Ueno A,, Naraba H,, Kojima F,, Ushikubi F,, Narumiya S,, Oh-ishi S . 2004. Prostaglandin receptors EP 2, EP 3, and IP mediate exudate formation in carrageenin-induced mouse pleurisy. J Pharmacol Exp Ther 311 : 1218 1224.
51. Yuhki K,, Ushikubi F,, Naraba H,, Ueno A,, Kato H,, Kojima F,, Narumiya S,, Sugimoto Y,, Matsushita M,, Oh-Ishi S . 2008. Prostaglandin I 2 plays a key role in zymosan-induced mouse pleurisy. J Pharmacol Exp Ther 325 : 601 609.
52. Saxena PN,, Beg MM,, Singhal KC,, Ahmad M . 1979. Prostaglandin-like activity in the cerebrospinal fluid of febrile patients. Indian J Med Res 70 : 495 498.
53. Dantzer R,, Konsman JP,, Bluthé RM,, Kelley KW . 2000. Neural and humoral pathways of communication from the immune system to the brain: parallel or convergent? Auton Neurosci 85 : 60 65.
54. Ek M,, Kurosawa M,, Lundeberg T,, Ericsson A . 1998. Activation of vagal afferents after intravenous injection of interleukin-1beta: role of endogenous prostaglandins. J Neurosci 18 : 9471 9479.
55. Lazarus M,, Yoshida K,, Coppari R,, Bass CE,, Mochizuki T,, Lowell BB,, Saper CB . 2007. EP3 prostaglandin receptors in the median preoptic nucleus are critical for fever responses. Nat Neurosci 10 : 1131 1133.
56. Ushikubi F,, Segi E,, Sugimoto Y,, Murata T,, Matsuoka T,, Kobayashi T,, Hizaki H,, Tuboi K,, Katsuyama M,, Ichikawa A,, Tanaka T,, Yoshida N,, Narumiya S . 1998. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP 3 . Nature 395 : 281 284.
57. Madden CJ,, Morrison SF . 2003. Excitatory amino acid receptor activation in the raphe pallidus area mediates prostaglandin-evoked thermogenesis. Neuroscience 122 : 5 15.
58. Madden CJ,, Morrison SF . 2004. Excitatory amino acid receptors in the dorsomedial hypothalamus mediate prostaglandin-evoked thermogenesis in brown adipose tissue. Am J Physiol Regul Integr Comp Physiol 286 : R320 R325.
59. Morrison SF . 2001. Differential regulation of sympathetic outflows to vasoconstrictor and thermoregulatory effectors. Ann N Y Acad Sci 940 : 286 298.
60. Morrison SF . 2003. Raphe pallidus neurons mediate prostaglandin E 2-evoked increases in brown adipose tissue thermogenesis. Neuroscience 121 : 17 24.
61. Morrison SF . 2004. Central pathways controlling brown adipose tissue thermogenesis. News Physiol Sci 19 : 67 74.
62. Ahmadi S,, Lippross S,, Neuhuber WL,, Zeilhofer HU . 2002. PGE 2 selectively blocks inhibitory glycinergic neurotransmission onto rat superficial dorsal horn neurons. Nat Neurosci 5 : 34 40.
63. Juhlin L,, Michaëlsson G . 1969. Cutaneous vascular reactions to prostaglandins in healthy subjects and in patients with urticaria and atopic dermatitis. Acta Derm Venereol 49 : 251 261.
64. Lin CR,, Amaya F,, Barrett L,, Wang H,, Takada J,, Samad TA,, Woolf CJ . 2006. Prostaglandin E 2 receptor EP4 contributes to inflammatory pain hypersensitivity. J Pharmacol Exp Ther 319 : 1096 1103.
65. McAdam BF,, Mardini IA,, Habib A,, Burke A,, Lawson JA,, Kapoor S,, FitzGerald GA . 2000. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J Clin Invest 105 : 1473 1482.
66. Moriyama T,, Higashi T,, Togashi K,, Iida T,, Segi E,, Sugimoto Y,, Tominaga T,, Narumiya S,, Tominaga M . 2005. Sensitization of TRPV1 by EP 1 and IP reveals peripheral nociceptive mechanism of prostaglandins. Mol Pain 1 : 3. doi:10.1186/1744-8069-1-3.
67. Murata T,, Ushikubi F,, Matsuoka T,, Hirata M,, Yamasaki A,, Sugimoto Y,, Ichikawa A,, Aze Y,, Tanaka T,, Yoshida N,, Ueno A,, Oh-ishi S,, Narumiya S . 1997. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388 : 678 682.
68. Reinold H,, Ahmadi S,, Depner UB,, Layh B,, Heindl C,, Hamza M,, Pahl A,, Brune K,, Narumiya S,, Müller U,, Zeilhofer HU . 2005. Spinal inflammatory hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype. J Clin Invest 115 : 673 679.
69. Solomon LM,, Juhlin L,, Kirschenbaum MB . 1968. Prostaglandin on cutaneous vasculature. J Invest Dermatol 51 : 280 282.
70. Ueno A,, Matsumoto H,, Naraba H,, Ikeda Y,, Ushikubi F,, Matsuoka T,, Narumiya S,, Sugimoto Y,, Ichikawa A,, Oh-ishi S . 2001. Major roles of prostanoid receptors IP and EP 3 in endotoxin-induced enhancement of pain perception. Biochem Pharmacol 62 : 157 160.
71. Smyth EM,, Grosser T,, Wang M,, Yu Y,, FitzGerald GA . 2009. Prostanoids in health and disease. J Lipid Res 50( Suppl) : S423 S428.
72. García Rodríguez LA,, Tacconelli S,, Patrignani P . 2008. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 52 : 1628 1636.
73. Grosser T,, Fries S,, FitzGerald GA . 2006. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116 : 4 15.
74. Xiao CY,, Hara A,, Yuhki K,, Fujino T,, Ma H,, Okada Y,, Takahata O,, Yamada T,, Murata T,, Narumiya S,, Ushikubi F . 2001. Roles of prostaglandin I 2 and thromboxane A 2 in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors. Circulation 104 : 2210 2215.
75. Degousee N,, Fazel S,, Angoulvant D,, Stefanski E,, Pawelzik SC,, Korotkova M,, Arab S,, Liu P,, Lindsay TF,, Zhuo S,, Butany J,, Li RK,, Audoly L,, Schmidt R,, Angioni C,, Geisslinger G,, Jakobsson PJ,, Rubin BB . 2008. Microsomal prostaglandin E 2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction. Circulation 117 : 1701 1710.
76. Qian JY,, Harding P,, Liu Y,, Shesely E,, Yang XP,, LaPointe MC . 2008. Reduced cardiac remodeling and function in cardiac-specific EP 4 receptor knockout mice with myocardial infarction. Hypertension 51 : 560 566.
77. Bunting S,, Moncada S,, Vane JR . 1983. The prostacyclin-thromboxane A 2 balance: pathophysiological and therapeutic implications. Br Med Bull 39 : 271 276.
78. FitzGerald GA . 2003. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2 : 879 890.
79. de Nucci G,, Gryglewski RJ,, Warner TD,, Vane JR . 1988. Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci U S A 85 : 2334 2338.
80. Palmer RM,, Ferrige AG,, Moncada S . 1987. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327 : 524 526.
81. Ellis EF,, Oelz O,, Roberts LJ II,, Payne NA,, Sweetman BJ,, Nies AS,, Oates JA . 1976. Coronary arterial smooth muscle contraction by a substance released from platelets: evidence that it is thromboxane A 2 . Science 193 : 1135 1137.
82. Hamberg M,, Svensson J,, Samuelsson B . 1975. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A 72 : 2994 2998.
83. Salzman PM,, Salmon JA,, Moncada S . 1980. Prostacyclin and thromboxane A 2 synthesis by rabbit pulmonary artery. J Pharmacol Exp Ther 215 : 240 247.
84. Rocca B,, Secchiero P,, Ciabattoni G,, Ranelletti FO,, Catani L,, Guidotti L,, Melloni E,, Maggiano N,, Zauli G,, Patrono C . 2002. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A 99 : 7634 7639.
85. Aronoff DM,, Carstens JK,, Chen GH,, Toews GB,, Peters-Golden M . 2006. Short communication: differences between macrophages and dendritic cells in the cyclic AMP-dependent regulation of lipopolysaccharide-induced cytokine and chemokine synthesis. J Interferon Cytokine Res 26 : 827 833.
86. Luo M,, Jones SM,, Phare SM,, Coffey MJ,, Peters-Golden M,, Brock TG . 2004. Protein kinase A inhibits leukotriene synthesis by phosphorylation of 5-lipoxygenase on serine 523. J Biol Chem 279 : 41512 41520.
87. van der Pouw Kraan TC,, van Lier RA,, Aarden LA . 1995. PGE 2 and the immune response. A central role for prostaglandin E 2 in downregulating the inflammatory immune response. Mol Med Today 1 : 61.
88. Aronoff DM,, Canetti C,, Peters-Golden M . 2004. Prostaglandin E 2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. J Immunol 173 : 559 565.
89. Rossi AG,, McCutcheon JC,, Roy N,, Chilvers ER,, Haslett C,, Dransfield I . 1998. Regulation of macrophage phagocytosis of apoptotic cells by cAMP. J Immunol 160 : 3562 3568.
90. Serezani CH,, Chung J,, Ballinger MN,, Moore BB,, Aronoff DM,, Peters-Golden M . 2007. Prostaglandin E 2 suppresses bacterial killing in alveolar macrophages by inhibiting NADPH oxidase. Am J Respir Cell Mol Biol 37 : 562 570.
91. Soares AC,, Souza DG,, Pinho V,, Vieira AT,, Barsante MM,, Nicoli JR,, Teixeira M . 2003. Impaired host defense to Klebsiella pneumoniae infection in mice treated with the PDE4 inhibitor rolipram. Br J Pharmacol 140 : 855 862.
92. Weinberg DA,, Weston LK,, Kaplan JE . 1985. Influence of prostaglandin I 2 on fibronectin-mediated phagocytosis in vivo and in vitro. J Leukoc Biol 37 : 151 159.
93. Ydrenius L,, Majeed M,, Rasmusson BJ,, Stendahl O,, Särndahl E . 2000. Activation of cAMP-dependent protein kinase is necessary for actin rearrangements in human neutrophils during phagocytosis. J Leukoc Biol 67 : 520 528.
94. Aronoff DM,, Peres CM,, Serezani CH,, Ballinger MN,, Carstens JK,, Coleman N,, Moore BB,, Peebles RS,, Faccioli LH,, Peters-Golden M . 2007. Synthetic prostacyclin analogs differentially regulate macrophage function via distinct analog-receptor binding specificities. J Immunol 178 : 1628 1634.
95. Brandwein SR . 1986. Regulation of interleukin 1 production by mouse peritoneal macrophages. Effects of arachidonic acid metabolites, cyclic nucleotides, and interferons. J Biol Chem 261 : 8624 8632.
96. Kunkel SL,, Spengler M,, May MA,, Spengler R,, Larrick J,, Remick D . 1988. Prostaglandin E 2 regulates macrophage-derived tumor necrosis factor gene expression. J Biol Chem 263 : 5380 5384.
97. Kunkel SL,, Wiggins RC,, Chensue SW,, Larrick J . 1986. Regulation of macrophage tumor necrosis factor production by prostaglandin E 2 . Biochem Biophys Res Commun 137 : 404 410.
98. Takayama K,, García-Cardena G,, Sukhova GK,, Comander J,, Gimbrone MA Jr,, Libby P . 2002. Prostaglandin E 2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem 277 : 44147 44154.
99. van der Pouw Kraan TC,, Boeije LC,, Snijders A,, Smeenk RJ,, Wijdenes J,, Aarden LA . 1996. Regulation of IL-12 production by human monocytes and the influence of prostaglandin E 2 . Ann N Y Acad Sci 795 : 147 157.
100. Xu XJ,, Reichner JS,, Mastrofrancesco B,, Henry WL Jr,, Albina JE . 2008. Prostaglandin E 2 suppresses lipopolysaccharide-stimulated IFN-β production. J Immunol 180 : 2125 2131.
101. Harizi H,, Juzan M,, Pitard V,, Moreau JF,, Gualde N . 2002. Cyclooxygenase-2-issued prostaglandin E 2 enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J Immunol 168 : 2255 2263.
102. Hinson RM,, Williams JA,, Shacter E . 1996. Elevated interleukin 6 is induced by prostaglandin E 2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc Natl Acad Sci U S A 93 : 4885 4890.
103. Starczewski M,, Voigtmann R,, Peskar BA,, Peskar BM . 1984. Plasma levels of 15-keto-13,14-dihydro-prostaglandin E 2 in patients with bronchogenic carcinoma. Prostaglandins Leukot Med 13 : 249 258.
104. Hayek MG,, Mura C,, Wu D,, Beharka AA,, Han SN,, Paulson KE,, Hwang D,, Meydani SN . 1997. Enhanced expression of inducible cyclooxygenase with age in murine macrophages. J Immunol 159 : 2445 2451.
105. Medjane S,, Raymond B,, Wu Y,, Touqui L . 2005. Impact of CFTR ΔF508 mutation on prostaglandin E 2 production and type IIA phospholipase A 2 expression by pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol 289 : L816 L824.
106. Strandvik B,, Svensson E,, Seyberth HW . 1996. Prostanoid biosynthesis in patients with cystic fibrosis. Prostaglandins Leukot Essent Fatty Acids 55 : 419 425.
107. Levy BD,, Clish CB,, Schmidt B,, Gronert K,, Serhan CN . 2001. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2 : 612 619.
108. Hong S,, Gronert K,, Devchand PR,, Moussignac RL,, Serhan CN . 2003. Novel docosatrienes and 17 S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 278 : 14677 14687.
109. Marcheselli VL,, Hong S,, Lukiw WJ,, Tian XH,, Gronert K,, Musto A,, Hardy M,, Gimenez JM,, Chiang N,, Serhan CN,, Bazan NG . 2003. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 278 : 43807 43817.
110. Serhan CN,, Clish CB,, Brannon J,, Colgan SP,, Chiang N,, Gronert K . 2000. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 192 : 1197 1204.
111. Serhan CN,, Hong S,, Gronert K,, Colgan SP,, Devchand PR,, Mirick G,, Moussignac RL . 2002. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 196 : 1025 1037.
112. Clark RB,, Bishop-Bailey D,, Estrada-Hernandez T,, Hla T,, Puddington L,, Padula SJ . 2000. The nuclear receptor PPARγ and immunoregulation: PPARγ mediates inhibition of helper T cell responses. J Immunol 164 : 1364 1371.
113. Combs CK,, Johnson DE,, Karlo JC,, Cannady SB,, Landreth GE . 2000. Inflammatory mechanisms in Alzheimer’s disease: inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists. J Neurosci 20 : 558 567.
114. Diab A,, Deng C,, Smith JD,, Hussain RZ,, Phanavanh B,, Lovett-Racke AE,, Drew PD,, Racke MK . 2002. Peroxisome proliferator-activated receptor-γ agonist 15-deoxy-Δ 12,14-prostaglandin J 2 ameliorates experimental autoimmune encephalomyelitis. J Immunol 168 : 2508 2515.
115. Kawahito Y,, Kondo M,, Tsubouchi Y,, Hashiramoto A,, Bishop-Bailey D,, Inoue K,, Kohno M,, Yamada R,, Hla T,, Sano H . 2000. 15-Deoxy-Δ 12,14-PGJ 2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 106 : 189 197.
116. Reilly CM,, Oates JC,, Cook JA,, Morrow JD,, Halushka PV,, Gilkeson GS . 2000. Inhibition of mesangial cell nitric oxide in MRL/ lpr mice by prostaglandin J 2 and proliferator activation receptor-γ agonists. J Immunol 164 : 1498 1504.
117. Kim EH,, Na HK,, Surh YJ . 2006. Upregulation of VEGF by 15-deoxy-Δ 12,14-prostaglandin J 2 via heme oxygenase-1 and ERK1/2 signaling in MCF-7 cells. Ann N Y Acad Sci 1090 : 375 384.
118. Oliva JL,, Pérez-Sala D,, Castrillo A,, Martínez N,, Cañada FJ,, Boscá L,, Rojas JM . 2003. The cyclopentenone 15-deoxy-Δ 12,14-prostaglandin J 2 binds to and activates H-Ras. Proc Natl Acad Sci USA 100 : 4772 4777.
119. Renedo M,, Gayarre J,, García-Domínguez CA,, Pérez-Rodríguez A,, Prieto A,, Cañada FJ,, Rojas JM,, Pérez-Sala D . 2007. Modification and activation of Ras proteins by electrophilic prostanoids with different structure are site-selective. Biochemistry 46 : 6607 6616.
120. Khan MM . 1995. Regulation of IL-4 and IL-5 secretion by histamine and PGE 2 . Adv Exp Med Biol 383 : 35 42.
121. Jiang C,, Ting AT,, Seed B . 1998. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391 : 82 86.
122. Ricote M,, Li AC,, Willson TM,, Kelly CJ,, Glass CK . 1998. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391 : 79 82.
123. Cernuda-Morollón E,, Pineda-Molina E,, Cañada FJ,, Pérez-Sala D . 2001. 15-Deoxy-Δ 12,14-prostaglandin J 2 inhibition of NF-κB-DNA binding through covalent modification of the p50 subunit. J Biol Chem 276 : 35530 35536.
124. Rossi A,, Kapahi P,, Natoli G,, Takahashi T,, Chen Y,, Karin M,, Santoro MG . 2000. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature 403 : 103 108.
125. Straus DS,, Pascual G,, Li M,, Welch JS,, Ricote M,, Hsiang CH,, Sengchanthalangsy LL,, Ghosh G,, Glass CK . 2000. 15-Deoxy-Δ 12,14-prostaglandin J 2 inhibits multiple steps in the NF-κB signaling pathway. Proc Natl Acad Sci U S A 97 : 4844 4849.
126. Jackson SM,, Parhami F,, Xi XP,, Berliner JA,, Hsueh WA,, Law RE,, Demer LL . 1999. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 19 : 2094 2104.
127. Pasceri V,, Wu HD,, Willerson JT,, Yeh ET . 2000. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation 101 : 235 238.
128. Zhang X,, Wang JM,, Gong WH,, Mukaida N,, Young HA . 2001. Differential regulation of chemokine gene expression by 15-deoxy-Δ 12,14 prostaglandin J 2 . J Immunol 166 : 7104 7111.
129. Lawrence T . 2002. Modulation of inflammation in vivo through induction of the heat shock response, effects on NF-κB activation. Inflamm Res 51 : 108 109.
130. Bishop-Bailey D,, Hla T . 1999. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Δ 12,14-prostaglandin J 2 . J Biol Chem 274 : 17042 17048.
131. Khoshnan A,, Tindell C,, Laux I,, Bae D,, Bennett B,, Nel AE . 2000. The NF-κB cascade is important in Bcl-x L expression and for the anti-apoptotic effects of the CD28 receptor in primary human CD4 + lymphocytes. J Immunol 165 : 1743 1754.
132. Lawrence T,, Gilroy DW,, Colville-Nash PR,, Willoughby DA . 2001. Possible new role for NF-κB in the resolution of inflammation. Nat Med 7 : 1291 1297.
133. Ward C,, Dransfield I,, Murray J,, Farrow SN,, Haslett C,, Rossi AG . 2002. Prostaglandin D 2 and its metabolites induce caspase-dependent granulocyte apoptosis that is mediated via inhibition of IκBα degradation using a peroxisome proliferator-activated receptor-γ-independent mechanism. J Immunol 168 : 6232 6243.
134. Trivedi SG,, Newson J,, Rajakariar R,, Jacques TS,, Hannon R,, Kanaoka Y,, Eguchi N,, Colville-Nash P,, Gilroy DW . 2006. Essential role for hematopoietic prostaglandin D 2 synthase in the control of delayed type hypersensitivity. Proc Natl Acad Sci U S A 103 : 5179 5184.
135. Lewis RA,, Austen KF,, Drazen JM,, Clark DA,, Marfat A,, Corey EJ . 1980. Slow reacting substances of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources. Proc Natl Acad Sci U S A 77 : 3710 3714.
136. Borgeat P,, Samuelsson B . 1979. Arachidonic acid metabolism in polymorphonuclear leukocytes: effects of ionophore A23187. Proc Natl Acad Sci U S A 76 : 2148 2152.
137. Smith MJ . 1979. Prostaglandins and the polymorphonuclear leucocyte. Agents Actions Suppl 1979( 6) : 91 103.
138. Funk CD . 2001. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294 : 1871 1875.
139. Minami M,, Ohno S,, Kawasaki H,, Rådmark O,, Samuelsson B,, Jörnvall H,, Shimizu T,, Seyama Y,, Suzuki K . 1987. Molecular cloning of a cDNA coding for human leukotriene A 4 hydrolase. Complete primary structure of an enzyme involved in eicosanoid synthesis. J Biol Chem 262 : 13873 13876.
140. Hammarström S,, Orning L,, Bernström K . 1985. Metabolism of leukotrienes. Mol Cell Biochem 69 : 7 16.
141. Lam BK,, Gagnon L,, Austen KF,, Soberman RJ . 1990. The mechanism of leukotriene B 4 export from human polymorphonuclear leukocytes. J Biol Chem 265 : 13438 13441.
142. Leier I,, Jedlitschky G,, Buchholz U,, Keppler D . 1994. Characterization of the ATP-dependent leukotriene C 4 export carrier in mastocytoma cells. Eur J Biochem 220 : 599 606.
143. Rouzer CA,, Samuelsson B . 1985. On the nature of the 5-lipoxygenase reaction in human leukocytes: enzyme purification and requirement for multiple stimulatory factors. Proc Natl Acad Sci U S A 82 : 6040 6044.
144. Ochi K,, Yoshimoto T,, Yamamoto S,, Taniguchi K,, Miyamoto T . 1983. Arachidonate 5-lipoxygenase of guinea pig peritoneal polymorphonuclear leukocytes. Activation by adenosine 5′-triphosphate. J Biol Chem 258 : 5754 5758.
145. Werz O,, Szellas D,, Steinhilber D,, Rådmark O . 2002. Arachidonic acid promotes phosphorylation of 5-lipoxygenase at Ser-271 by MAPK-activated protein kinase 2 (MK2). J Biol Chem 277 : 14793 14800.
146. Kanaoka Y,, Boyce JA . 2004. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J Immunol 173 : 1503 1510.
147. Tager AM,, Luster AD . 2003. BLT1 and BLT2: the leukotriene B 4 receptors. Prostaglandins Leukot Essent Fatty Acids 69 : 123 134.
148. Lynch KR,, O’Neill GP,, Liu Q,, Im DS,, Sawyer N,, Metters KM,, Coulombe N,, Abramovitz M,, Figueroa DJ,, Zeng Z,, Connolly BM,, Bai C,, Austin CP,, Chateauneuf A,, Stocco R,, Greig GM,, Kargman S,, Hooks SB,, Hosfield E,, Williams DL Jr,, Ford-Hutchinson AW,, Caskey CT,, Evans JF . 1999. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399 : 789 793.
149. Beller TC,, Friend DS,, Maekawa A,, Lam BK,, Austen KF,, Kanaoka Y . 2004. Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis. Proc Natl Acad Sci U S A 101 : 3047 3052.
150. Hui Y,, Cheng Y,, Smalera I,, Jian W,, Goldhahn L,, Fitzgerald GA,, Funk CD . 2004. Directed vascular expression of human cysteinyl leukotriene 2 receptor modulates endothelial permeability and systemic blood pressure. Circulation 110 : 3360 3366.
151. Sousa AR,, Parikh A,, Scadding G,, Corrigan CJ,, Lee TH . 2002. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 347 : 1493 1499.
152. Devchand PR,, Keller H,, Peters JM,, Vazquez M,, Gonzalez FJ,, Wahli W . 1996. The PPARα-leukotriene B 4 pathway to inflammation control. Nature 384 : 39 43.
153. Krey G,, Braissant O,, L’Horset F,, Kalkhoven E,, Perroud M,, Parker MG,, Wahli W . 1997. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 11 : 779 791.
154. Lin Q,, Ruuska SE,, Shaw NS,, Dong D,, Noy N . 1999. Ligand selectivity of the peroxisome proliferator-activated receptor α. Biochemistry 38 : 185 190.
155. Narala VR,, Adapala RK,, Suresh MV,, Brock TG,, Peters-Golden M,, Reddy RC . 2010. Leukotriene B 4 is a physiologically relevant endogenous peroxisome proliferator-activated receptor-α agonist. J Biol Chem 285 : 22067 22074.
156. Borgeat P,, Naccache PH . 1990. Biosynthesis and biological activity of leukotriene B 4 . Clin Biochem 23 : 459 468.
157. Ott VL,, Cambier JC,, Kappler J,, Marrack P,, Swanson BJ . 2003. Mast cell-dependent migration of effector CD8 + T cells through production of leukotriene B 4 . Nat Immunol 4 : 974 981.
158. Woodward DF,, Krauss AH,, Nieves AL,, Spada CS . 1991. Studies on leukotriene D 4 as an eosinophil chemoattractant. Drugs Exp Clin Res 17 : 543 548.
159. Björk J,, Hedqvist P,, Arfors KE . 1982. Increase in vascular permeability induced by leukotriene B 4 and the role of polymorphonuclear leukocytes. Inflammation 6 : 189 200.
160. Dahlén SE,, Björk J,, Hedqvist P,, Arfors KE,, Hammarström S,, Lindgren JA,, Samuelsson B . 1981. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci U S A 78 : 3887 3891.
161. Hedqvist P,, Dahlén SE . 1983. Pulmonary and vascular effects of leukotrienes imply involvement in asthma and inflammation. Adv Prostaglandin Thromboxane Leukot Res 11 : 27 32.
162. Orange RP,, Stechschulte DJ,, Austen KF . 1969. Cellular mechanisms involved in the release of slow reacting substance of anaphylaxis. Fed Proc 28 : 1710 1715.
163. Svensjö E . 1978. Bradykinin and prostaglandin E 1, E 2 and F -induced macromolecular leakage in the hamster cheek pouch. Prostaglandins Med 1 : 397 410.
164. Werz O,, Steinhilber D . 2005. Development of 5-lipoxygenase inhibitors—lessons from cellular enzyme regulation. Biochem Pharmacol 70 : 327 333.
165. Israel E,, Rubin P,, Kemp JP,, Grossman J,, Pierson W,, Siegel SC,, Tinkelman D,, Murray JJ,, Busse W,, Segal AT,, Fish J,, Kaiser HB,, Ledford D,, Wenzel S,, Rosenthal R,, Cohn J,, Lanni C,, Pearlman H,, Karahalios P,, Drazen JM . 1993. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 119 : 1059 1066.
166. Knorr B,, Matz J,, Bernstein JA,, Nguyen H,, Seidenberg BC,, Reiss TF,, Becker A , Pediatric Montelukast Study Group . 1998. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. JAMA 279 : 1181 1186.
167. Suissa S,, Dennis R,, Ernst P,, Sheehy O,, Wood-Dauphinee S . 1997. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 126 : 177 183.
168. Spanbroek R,, Grabner R,, Lotzer K,, Hildner M,, Urbach A,, Ruhling K,, Moos MP,, Kaiser B,, Cohnert TU,, Wahlers T,, Zieske A,, Plenz G,, Robenek H,, Salbach P,, Kuhn H,, Radmark O,, Samuelsson B,, Habenicht AJ . 2003. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci U S A 100 : 1238 1243.
169. Qiu H,, Gabrielsen A,, Agardh HE,, Wan M,, Wetterholm A,, Wong CH,, Hedin U,, Swedenborg J,, Hansson GK,, Samuelsson B,, Paulsson-Berne G,, Haeggström JZ . 2006. Expression of 5-lipoxygenase and leukotriene A 4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci U S A 103 : 8161 8166.
170. Aiello RJ,, Bourassa PA,, Lindsey S,, Weng W,, Freeman A,, Showell HJ . 2002. Leukotriene B 4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol 22 : 443 449.
171. Bäck M,, Bu DX,, Bränström R,, Sheikine Y,, Yan ZQ,, Hansson GK . 2005. Leukotriene B 4 signaling through NF-κB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci U S A 102 : 17501 17506.
172. Uzonyi B,, Lötzer K,, Jahn S,, Kramer C,, Hildner M,, Bretschneider E,, Radke D,, Beer M,, Vollandt R,, Evans JF,, Funk CD,, Habenicht AJ . 2006. Cysteinyl leukotriene 2 receptor and protease-activated receptor 1 activate strongly correlated early genes in human endothelial cells. Proc Natl Acad Sci U S A 103 : 6326 6331.
173. Zhao L,, Moos MP,, Gräbner R,, Pédrono F,, Fan J,, Kaiser B,, John N,, Schmidt S,, Spanbroek R,, Lötzer K,, Huang L,, Cui J,, Rader DJ,, Evans JF,, Habenicht AJ,, Funk CD . 2004. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med 10 : 966 973.
174. Helgadottir A,, Manolescu A,, Helgason A,, Thorleifsson G,, Thorsteinsdottir U,, Gudbjartsson DF,, Gretarsdottir S,, Magnusson KP,, Gudmundsson G,, Hicks A,, Jonsson T,, Grant SF,, Sainz J,, O’Brien SJ,, Sveinbjornsdottir S,, Valdimarsson EM,, Matthiasson SE,, Levey AI,, Abramson JL,, Reilly MP,, Vaccarino V,, Wolfe ML,, Gudnason V,, Quyyumi AA,, Topol EJ,, Rader DJ,, Thorgeirsson G,, Gulcher JR,, Hakonarson H,, Kong A,, Stefansson K . 2006. A variant of the gene encoding leukotriene A 4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 38 : 68 74.
175. Helgadottir A,, Manolescu A,, Thorleifsson G,, Gretarsdottir S,, Jonsdottir H,, Thorsteinsdottir U,, Samani NJ,, Gudmundsson G,, Grant SF,, Thorgeirsson G,, Sveinbjornsdottir S,, Valdimarsson EM,, Matthiasson SE,, Johannsson H,, Gudmundsdottir O,, Gurney ME,, Sainz J,, Thorhallsdottir M,, Andresdottir M,, Frigge ML,, Topol EJ,, Kong A,, Gudnason V,, Hakonarson H,, Gulcher JR,, Stefansson K . 2004. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 36 : 233 239.
176. Kajimoto K,, Shioji K,, Ishida C,, Iwanaga Y,, Kokubo Y,, Tomoike H,, Miyazaki S,, Nonogi H,, Goto Y,, Iwai N . 2005. Validation of the association between the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a Japanese population. Circ J 69 : 1029 1034.
177. Hakonarson H,, Thorvaldsson S,, Helgadottir A,, Gudbjartsson D,, Zink F,, Andresdottir M,, Manolescu A,, Arnar DO,, Andersen K,, Sigurdsson A,, Thorgeirsson G,, Jonsson A,, Agnarsson U,, Bjornsdottir H,, Gottskalksson G,, Einarsson A,, Gudmundsdottir H,, Adalsteinsdottir AE,, Gudmundsson K,, Kristjansson K,, Hardarson T,, Kristinsson A,, Topol EJ,, Gulcher J,, Kong A,, Gurney M,, Thorgeirsson G,, Stefansson K . 2005. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA 293 : 2245 2256.
178. Peters-Golden M,, Canetti C,, Mancuso P,, Coffey MJ . 2005. Leukotrienes: underappreciated mediators of innate immune responses. J Immunol 174 : 589 594.
179. Bailie MB,, Standiford TJ,, Laichalk LL,, Coffey MJ,, Strieter R,, Peters-Golden M . 1996. Leukotriene-deficient mice manifest enhanced lethality from Klebsiella pneumonia in association with decreased alveolar macrophage phagocytic and bactericidal activities. J Immunol 157 : 5221 5224.
180. Mancuso P,, Lewis C,, Serezani CH,, Goel D,, Peters-Golden M . 2010. Intrapulmonary administration of leukotriene B 4 enhances pulmonary host defense against pneumococcal pneumonia. Infect Immun 78 : 2264 2271.
181. Medeiros AI,, Sá-Nunes A,, Turato WM,, Secatto A,, Frantz FG,, Sorgi CA,, Serezani CH,, Deepe GS Jr,, Faccioli LH . 2008. Leukotrienes are potent adjuvant during fungal infection: effects on memory T cells. J Immunol 181 : 8544 8551.
182. Peres CM,, de Paula L,, Medeiros AI,, Sorgi CA,, Soares EG,, Carlos D,, Peters-Golden M,, Silva CL,, Faccioli LH . 2007. Inhibition of leukotriene biosynthesis abrogates the host control of Mycobacterium tuberculosis . Microbes Infect 9 : 483 489.
183. Schultz MJ,, Wijnholds J,, Peppelenbosch MP,, Vervoordeldonk MJ,, Speelman P,, van Deventer SJ,, Borst P,, van der Poll T . 2001. Mice lacking the multidrug resistance protein 1 are resistant to Streptococcus pneumoniae-induced pneumonia. J Immunol 166 : 4059 4064.
184. Serezani CH,, Perrela JH,, Russo M,, Peters-Golden M,, Jancar S . 2006. Leukotrienes are essential for the control of Leishmania amazonensis infection and contribute to strain variation in susceptibility. J Immunol 177 : 3201 3208.
185. Serezani CH,, Aronoff DM,, Jancar S,, Mancuso P,, Peters-Golden M . 2005. Leukotrienes enhance the bactericidal activity of alveolar macrophages against Klebsiella pneumoniae through the activation of NADPH oxidase. Blood 106 : 1067 1075.
186. Ballinger MN,, Hubbard LL,, McMillan TR,, Toews GB,, Peters-Golden M,, Paine R III,, Moore BB . 2008. Paradoxical role of alveolar macrophage-derived granulocyte-macrophage colony-stimulating factor in pulmonary host defense post-bone marrow transplantation. Am J Physiol Lung Cell Mol Physiol 295 : L114 L122.
187. Balter MS,, Toews GB,, Peters-Golden M . 1989. Multiple defects in arachidonate metabolism in alveolar macrophages from young asymptomatic smokers. J Lab Clin Med 114 : 662 673.
188. Cederholm T,, Lindgren JA,, Palmblad J . 2000. Impaired leukotriene C 4 generation in granulocytes from protein-energy malnourished chronically ill elderly. J Intern Med 247 : 715 722.
189. Coffey MJ,, Phare SM,, Kazanjian PH,, Peters-Golden M . 1996. 5-Lipoxygenase metabolism in alveolar macrophages from subjects infected with the human immunodeficiency virus. J Immunol 157 : 393 399.
190. Coffey MJ,, Wilcoxen SE,, Phare SM,, Simpson RU,, Gyetko MR,, Peters-Golden M . 1994. Reduced 5-lipoxygenase metabolism of arachidonic acid in macrophages from 1,25-dihydroxyvitamin D3-deficient rats. Prostaglandins 48 : 313 329.
191. Jubiz W,, Draper RE,, Gale J,, Nolan G . 1984. Decreased leukotriene B 4 synthesis by polymorphonuclear leukocytes from male patients with diabetes mellitus. Prostaglandins Leukot Med 14 : 305 311.
192. Lärfars G,, Lantoine F,, Devynck MA,, Palmblad J,, Gyllenhammar H . 1999. Activation of nitric oxide release and oxidative metabolism by leukotrienes B 4, C 4, and D 4 in human polymorphonuclear leukocytes. Blood 93 : 1399 1405.
193. Talvani A,, Machado FS,, Santana GC,, Klein A,, Barcelos L,, Silva JS,, Teixeira MM . 2002. Leukotriene B 4 induces nitric oxide synthesis in Trypanosoma cruzi-infected murine macrophages and mediates resistance to infection. Infect Immun 70 : 4247 4253.
194. Flamand L,, Tremblay MJ,, Borgeat P . 2007. Leukotriene B 4 triggers the in vitro and in vivo release of potent antimicrobial agents. J Immunol 178 : 8036 8045.
195. Powell WS,, Gravelle F,, Gravel S . 1992. Metabolism of 5( S)-hydroxy-6,8,11,14-eicosatetraenoic acid and other 5( S)-hydroxyeicosanoids by a specific dehydrogenase in human polymorphonuclear leukocytes. J Biol Chem 267 : 19233 19241.
196. Graham FD,, Erlemann KR,, Gravel S,, Rokach J,, Powell WS . 2009. Oxidative stress-induced changes in pyridine nucleotides and chemoattractant 5-lipoxygenase products in aging neutrophils. Free Radic Biol Med 47 : 62 71.
197. Powell WS,, Gravelle F,, Gravel S . 1994. Phorbol myristate acetate stimulates the formation of 5-oxo-6,8,11,14-eicosatetraenoic acid by human neutrophils by activating NADPH oxidase. J Biol Chem 269 : 25373 25380.
198. Cossette C,, Patel P,, Anumolu JR,, Sivendran S,, Lee GJ,, Gravel S,, Graham FD,, Lesimple A,, Mamer OA,, Rokach J,, Powell WS . 2008. Human neutrophils convert the sebum-derived polyunsaturated fatty acid sebaleic acid to a potent granulocyte chemoattractant. J Biol Chem 283 : 11234 11243.
199. Patel P,, Cossette C,, Anumolu JR,, Gravel S,, Lesimple A,, Mamer OA,, Rokach J,, Powell WS . 2008. Structural requirements for activation of the 5-oxo-6 E,8 Z, 11 Z,14 Z-eicosatetraenoic acid (5-oxo-ETE) receptor: identification of a mead acid metabolite with potent agonist activity. J Pharmacol Exp Ther 325 : 698 707.
200. Powell WS,, Chung D,, Gravel S . 1995. 5-Oxo-6,8,11,14-eicosatetraenoic acid is a potent stimulator of human eosinophil migration. J Immunol 154 : 4123 4132.
201. Powell WS,, Rokach J . 2005. Biochemistry, biology and chemistry of the 5-lipoxygenase product 5-oxo-ETE. Prog Lipid Res 44 : 154 183.
202. Brink CB,, Harvey BH,, Bodenstein J,, Venter DP,, Oliver DW . 2004. Recent advances in drug action and therapeutics: relevance of novel concepts in G-protein-coupled receptor and signal transduction pharmacology. Br J Clin Pharmacol 57 : 373 387.
203. Takeda S,, Kadowaki S,, Haga T,, Takaesu H,, Mitaku S . 2002. Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Lett 520 : 97 101.
204. Hosoi T,, Koguchi Y,, Sugikawa E,, Chikada A,, Ogawa K,, Tsuda N,, Suto N,, Tsunoda S,, Taniguchi T,, Ohnuki T . 2002. Identification of a novel human eicosanoid receptor coupled to G i/o . J Biol Chem 277 : 31459 31465.
205. Jones CE,, Holden S,, Tenaillon L,, Bhatia U,, Seuwen K,, Tranter P,, Turner J,, Kettle R,, Bouhelal R,, Charlton S,, Nirmala NR,, Jarai G,, Finan P . 2003. Expression and characterization of a 5-oxo-6 E,8 Z,11 Z,14 Z-eicosatetraenoic acid receptor highly expressed on human eosinophils and neutrophils. Mol Pharmacol 63 : 471 477.
206. Norgauer J,, Barbisch M,, Czech W,, Pareigis J,, Schwenk U,, Schröder JM . 1996. Chemotactic 5-oxo-icosatetraenoic acids activate a unique pattern of neutrophil responses. Analysis of phospholipid metabolism, intracellular Ca 2+ transients, actin reorganization, superoxide-anion production and receptor up-regulation. Eur J Biochem 236 : 1003 1009.
207. O’Flaherty JT,, Kuroki M,, Nixon AB,, Wijkander J,, Yee E,, Lee SL,, Smitherman PK,, Wykle RL,, Daniel LW . 1996. 5-Oxo-eicosanoids and hematopoietic cytokines cooperate in stimulating neutrophil function and the mitogen-activated protein kinase pathway. J Biol Chem 271 : 17821 17828.
208. Hosoi T,, Sugikawa E,, Chikada A,, Koguchi Y,, Ohnuki T . 2005. TG1019/OXE, a Gα i/o-protein-coupled receptor, mediates 5-oxo-eicosatetraenoic acid-induced chemotaxis. Biochem Biophys Res Commun 334 : 987 995.